MENU

Speakers


  • Dr. Silvia Anghel

    Dr. Silvia Anghel

    Senior Associate, Medidee

    BIOGRAPHY
  • Matthew Davies

    Matthew Davies

    Custom Service Leader, Cytiva

    BIOGRAPHY
  • Dominik de Cassan

    Dominik de Cassan

    R&D Leader - Membranes, Cytiva

    BIOGRAPHY
  • Chike Ejiofor

    Chike Ejiofor

    Product Manager Nucleic Acid Sample Preparation, Cytiva

    BIOGRAPHY
  • Philippe Etter

    Philippe Etter

    Senior Partner, Medidee

    BIOGRAPHY
  • Dr. Shamiram R. Feinglass, MD, MPH

    Dr. Shamiram R. Feinglass, MD, MPH

    CMO & VP Global Medical Affairs and Policy, Diagnostics and Life Sciences, Danaher Corporation

    BIOGRAPHY
  • Andrew Gane

    Andrew Gane

    Strategy and Technology Manager, Cytiva

    BIOGRAPHY
  • Donald Green, MSc

    Donald Green, MSc

    Senior Field Application Specialist, Genomics and Diagnostics, Cytiva

    BIOGRAPHY
  • Anja Drescher

    Anja Drescher

    Senior Application Specialist for Biacore systems, Cytiva

    BIOGRAPHY
  • Gabriel Fernandez de Pierola

    Gabriel Fernandez de Pierola

    General Manager, Genomics & Diagnostic Solutions, Cytiva

    BIOGRAPHY
  • Dr. Chris Fronczek

    Dr. Chris Fronczek

    Application Scientist, BioDot, Inc

    BIOGRAPHY
  • Klaus Hochleitner, PhD

    Klaus Hochleitner, PhD

    Global Technology Lead, Diagnostics, Cytiva

    BIOGRAPHY
  • Lee Jenkins

    Lee Jenkins

    Senior Product Leader, Cytiva

    BIOGRAPHY
  • Tom Lyons

    Tom Lyons

    Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva

    BIOGRAPHY
  • Pieter Mestdagh, PhD

    Pieter Mestdagh, PhD

    Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium

    BIOGRAPHY
  • Dr. Zahidul Mondle

    Dr. Zahidul Mondle

    Lead Technical Product Specialist, Cytiva

    BIOGRAPHY
  • Chris Norey

    Chris Norey

    R&D Leader, Genomics and Cellular Research, Cytiva

    BIOGRAPHY
  • Brendan O'Farrell, PhD

    Brendan O'Farrell, PhD

    President and Co-Founder, DCN Diagnostics

    BIOGRAPHY
  • David Raw

    David Raw

    Supplier Risk Management Leader, Cytiva

    BIOGRAPHY
  • Darren Rowles

    Darren Rowles

    President and CEO, Sona Nanotech

    BIOGRAPHY
  • Monika Seidel

    Monika Seidel

    Senior Development Scientist - Genomics and Cellular Research, Cytiva

    BIOGRAPHY
  • Stefanie Stepanow,  Dr. rer nat

    Stefanie Stepanow, Dr. rer nat

    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.

    BIOGRAPHY
  • Jonathan Thomas

    Jonathan Thomas

    Head of Contract Sales, Abingdon Health

    BIOGRAPHY
  • Amy Webster

    Amy Webster

    Custom Projects Leader, Cytiva

    BIOGRAPHY
  • David Wilson

    David Wilson

    Commercial Director, Diagnostics, Avacta Life Sciences

    BIOGRAPHY

Accelerating diagnostics test development

 
Each step in a diagnostic test’s journey—from raw material extraction to patient administration—can influence outcomes.  Advances in molecular biology, immunodiagnostics and rapid point-of-care (POC) testing are transforming diagnostics. New products and support services are providing the critical tools and components which enable clinicians to detect specific biomarkers and target treatments, ultimately resulting in better patient outcomes.
 
Recent events have increased the global focus and commitment to commercializing diagnsotic tests as quickly as possible as well as the challenges the industry has faced in developing and bringing these diagnostic tests to market in exceptional circumstances.  A wealth of technology, diverse expertise in areas such as material science, biochemistry, virology as well as a robust supply of critical components are fundamental to the successful development of every test.  Optimizing assays and kits for high sensitivity and accuracy is a common goal for all those involved in the development process. The need for close collaboration between diagnostic developers and component and material providers has never been stronger.
 
We invite you to our thought-provoking and interactive virtual open day showcasing recently launched products, solutions and services supporting the development of diagnostic assays and kits. Incorporating a program of webinars, panel discussion and new for the open day, a panel Q&A keynote. You will also be able to live chat with our product experts. 
 
If you would like to schedule a 30 minute meeting with one of our Cytiva experts please click here.
 
Event tracks available:
  1. Lateral flow design considerations

High performance, diagnostic rapid point-of-care (POC) flow-based tests can quickly deliver reliable results in challenging settings. When designing a new test and designing out a component in an existing test-what are the key considerations and what will be needed in the future?

  1. Accelerating diagnostic development with custom and design services

Commercializing a test or assay as quickly as possible is critical to success. Find out how diagnostic design services, lyophilization and custom capabilities can provide capacity, resources and expertise to improve speed to market now and in the future.

  1. Collaborating for effective diagnostic development

Strategic collaboration enables the development of diagnostic tests, assays and services for a wide range of applications. Hear about recent collaborations that have resulted in successful test development and set a path for future development.

  1. Simplifying your next-generation sequencing (NGS) workflow

High throughput NGS techniques are revolutionizing genomics from massively parallel whole genome sequencing to targeted sequencing approaches. Find out how to simplify your sequencing approaches for more detailed data, better diagnosis, and more targeted treatments to address current and future demands.

  1. Exploring single-cell omics opportunities

Recent technological advancements have made single-cell omics an increasingly powerful tool for diagnosis, treatment response prediction, and treatment selection, particularly for cancer. Learn about the opportunities for improving results in this growing field.

  1. Optimizing nucleic acid isolation

Recent years have seen the development and adaptation of several approaches for nucleic acid isolation, aiming to improve speed, throughput, and reproducibility. Find out how to optimize results, particularly for liquid biopsy and viral samples now and in the future.

 

All sessions will be available for on-demand viewing following the broadcast.

 


Speakers
  • Dr. Silvia Anghel

    Senior Associate, Medidee
    BIOGRAPHY
  • Matthew Davies

    Custom Service Leader, Cytiva
    BIOGRAPHY
  • Dominik de Cassan

    R&D Leader - Membranes, Cytiva
    BIOGRAPHY
  • Chike Ejiofor

    Product Manager Nucleic Acid Sample Preparation, Cytiva
    BIOGRAPHY
  • Philippe Etter

    Senior Partner, Medidee
    BIOGRAPHY
  • Dr. Shamiram R. Feinglass, MD, MPH

    CMO & VP Global Medical Affairs and Policy, Diagnostics and Life Sciences, Danaher Corporation
    BIOGRAPHY
  • Andrew Gane

    Strategy and Technology Manager, Cytiva
    BIOGRAPHY
  • Donald Green, MSc

    Senior Field Application Specialist, Genomics and Diagnostics, Cytiva
    BIOGRAPHY
  • Anja Drescher

    Senior Application Specialist for Biacore systems, Cytiva
    BIOGRAPHY
  • Gabriel Fernandez de Pierola

    General Manager, Genomics & Diagnostic Solutions, Cytiva
    BIOGRAPHY
  • Dr. Chris Fronczek

    Application Scientist, BioDot, Inc
    BIOGRAPHY
  • Klaus Hochleitner, PhD

    Global Technology Lead, Diagnostics, Cytiva
    BIOGRAPHY
  • Lee Jenkins

    Senior Product Leader, Cytiva
    BIOGRAPHY
  • Tom Lyons

    Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
    BIOGRAPHY
  • Pieter Mestdagh, PhD

    Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium
    BIOGRAPHY
  • Dr. Zahidul Mondle

    Lead Technical Product Specialist, Cytiva
    BIOGRAPHY
  • Chris Norey

    R&D Leader, Genomics and Cellular Research, Cytiva
    BIOGRAPHY
  • Brendan O'Farrell, PhD

    President and Co-Founder, DCN Diagnostics
    BIOGRAPHY
  • David Raw

    Supplier Risk Management Leader, Cytiva
    BIOGRAPHY
  • Darren Rowles

    President and CEO, Sona Nanotech
    BIOGRAPHY
  • Monika Seidel

    Senior Development Scientist - Genomics and Cellular Research, Cytiva
    BIOGRAPHY
  • Stefanie Stepanow, Dr. rer nat

    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.
    BIOGRAPHY
  • Jonathan Thomas

    Head of Contract Sales, Abingdon Health
    BIOGRAPHY
  • Amy Webster

    Custom Projects Leader, Cytiva
    BIOGRAPHY
  • David Wilson

    Commercial Director, Diagnostics, Avacta Life Sciences
    BIOGRAPHY

Webinars

Once the event opens, please click on the 'Go To Event' button and navigate to Webinars & Resources to view the webinars within the summit.

 

  • JUN 17, 2021 7:00 PM BST

    Extraction-free sensitive detection of viral RNA using direct RT-PCR chemistry

    Donald Green, MSc
    Senior Field Application Specialist, Genomics and Diagnostics, Cytiva
    BIOGRAPHY
  • JUN 17, 2021 4:00 PM BST

    Developing an effective regulatory pathway for IVD

    Philippe Etter
    Senior Partner, Medidee
    Dr. Silvia Anghel
    Senior Associate, Medidee
  • JUN 17, 2021 1:00 PM BST

    Panel Q&A: Accelerating diagnostic test development

    Dr. Zahidul Mondle
    Lead Technical Product Specialist, Cytiva
    Dominik de Cassan
    R&D Leader - Membranes, Cytiva
    Lee Jenkins
    Senior Product Leader, Cytiva
    Andrew Gane
    Strategy and Technology Manager, Cytiva
    Chike Ejiofor
    Product Manager Nucleic Acid Sample Preparation, Cytiva
    Matthew Davies
    Custom Service Leader, Cytiva
  • JUN 17, 2021 11:00 AM BST

    Practical advice for working with regulators

    Dr. Shamiram R. Feinglass, MD, MPH
    CMO & VP Global Medical Affairs and Policy, Diagnostics and Life Sciences, Danaher Corporation
    BIOGRAPHY
  • JUN 17, 2021 9:00 AM BST

    Considerations on the development of quantitative lateral flow assays

    Dominik de Cassan
    R&D Leader - Membranes, Cytiva
    BIOGRAPHY
  • Characterization and selection of antibodies for precision diagnostics using Biacore surface plasmon resonance technology

    Anja Drescher
    Senior Application Specialist for Biacore systems, Cytiva
    BIOGRAPHY
  • Lateral flow manufacturing strategies and scale-up towards Point-of-Care (POC) testing

    Dr. Chris Fronczek
    Application Scientist, BioDot, Inc
    BIOGRAPHY
  • Detection of mutations from liquid biopsies - applications in cancer diagnostics

    Monika Seidel
    Senior Development Scientist - Genomics and Cellular Research, Cytiva
    BIOGRAPHY
  • Minimizing risks of security of supply

    David Raw
    Supplier Risk Management Leader, Cytiva
    BIOGRAPHY
  • The varied application of Dried Blood Spot (DBS) sample collection during the COVID-19 Pandemic

    Dr. Zahidul Mondle
    Lead Technical Product Specialist, Cytiva
    BIOGRAPHY
  • Critical design considerations for POC diagnostic test development

    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    Brendan O'Farrell, PhD
    President and Co-Founder, DCN Diagnostics
    Darren Rowles
    President and CEO, Sona Nanotech
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
  • Eliminate temperature sensitivity with lyophilization technology

    Amy Webster
    Custom Projects Leader, Cytiva
    BIOGRAPHY
  • Diagnostics design and manufacturing: 2025

    Brendan O'Farrell, PhD
    President and Co-Founder, DCN Diagnostics
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
  • Applications of high throughput gene expression profiling in early drug discovery

    Pieter Mestdagh, PhD
    Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium
    BIOGRAPHY
  • Broaden your applications with magnetic bead conjugation

    Tom Lyons
    Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
    BIOGRAPHY
  • Lateral flow assay development from lab-based assay to diagnostics test prototype: introducing Cytiva's development services platform

    Lee Jenkins
    Senior Product Leader, Cytiva
    BIOGRAPHY
  • Effective RNA extraction for COVID-19 testing

    Gabriel Fernandez de Pierola
    General Manager, Genomics & Diagnostic Solutions, Cytiv...
    Chris Norey
    R&D Leader, Genomics and Cellular Research, Cytiva
  • The importance of working with your CMO during product development

    Jonathan Thomas
    Head of Contract Sales, Abingdon Health
    BIOGRAPHY
  • Approaches to sample preparation

    Stefanie Stepanow, Dr. rer nat
    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.
    BIOGRAPHY
  • Simplifying component Selection in Lateral Flow Assay Development

    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    BIOGRAPHY
  • Lateral flow design considerations
  • Simplifying component Selection in Lateral Flow Assay Development

    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    BIOGRAPHY
  • The importance of working with your CMO during product development

    Jonathan Thomas
    Head of Contract Sales, Abingdon Health
    BIOGRAPHY
  • Critical design considerations for POC diagnostic test development

    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    Brendan O'Farrell, PhD
    President and Co-Founder, DCN Diagnostics
    Darren Rowles
    President and CEO, Sona Nanotech
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
  • Lateral flow manufacturing strategies and scale-up towards Point-of-Care (POC) testing

    Dr. Chris Fronczek
    Application Scientist, BioDot, Inc
    BIOGRAPHY
  • Characterization and selection of antibodies for precision diagnostics using Biacore surface plasmon resonance technology

    Anja Drescher
    Senior Application Specialist for Biacore systems, Cytiva
    BIOGRAPHY
  • JUN 17, 2021 9:00 AM BST

    Considerations on the development of quantitative lateral flow assays

    Dominik de Cassan
    R&D Leader - Membranes, Cytiva
    BIOGRAPHY
  • Optimizing nucleic acid isolation
  • Approaches to sample preparation

    Stefanie Stepanow, Dr. rer nat
    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.
    BIOGRAPHY
  • Effective RNA extraction for COVID-19 testing

    Gabriel Fernandez de Pierola
    General Manager, Genomics & Diagnostic Solutions, Cytiv...
    Chris Norey
    R&D Leader, Genomics and Cellular Research, Cytiva
  • The varied application of Dried Blood Spot (DBS) sample collection during the COVID-19 Pandemic

    Dr. Zahidul Mondle
    Lead Technical Product Specialist, Cytiva
    BIOGRAPHY
  • Accelerating diagnostic development with custom and design services
  • Lateral flow assay development from lab-based assay to diagnostics test prototype: introducing Cytiva's development services platform

    Lee Jenkins
    Senior Product Leader, Cytiva
    BIOGRAPHY
  • Broaden your applications with magnetic bead conjugation

    Tom Lyons
    Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
    BIOGRAPHY
  • Eliminate temperature sensitivity with lyophilization technology

    Amy Webster
    Custom Projects Leader, Cytiva
    BIOGRAPHY
  • JUN 17, 2021 7:00 PM BST

    Extraction-free sensitive detection of viral RNA using direct RT-PCR chemistry

    Donald Green, MSc
    Senior Field Application Specialist, Genomics and Diagnostics, Cytiva
    BIOGRAPHY
  • SIMPLIFYING YOUR NGS WORKFLOW
  • Applications of high throughput gene expression profiling in early drug discovery

    Pieter Mestdagh, PhD
    Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium
    BIOGRAPHY
  • Detection of mutations from liquid biopsies - applications in cancer diagnostics

    Monika Seidel
    Senior Development Scientist - Genomics and Cellular Research, Cytiva
    BIOGRAPHY
  • Collaborating for effective diagnostic development
  • Minimizing risks of security of supply

    David Raw
    Supplier Risk Management Leader, Cytiva
    BIOGRAPHY
  • JUN 17, 2021 11:00 AM BST

    Practical advice for working with regulators

    Dr. Shamiram R. Feinglass, MD, MPH
    CMO & VP Global Medical Affairs and Policy, Diagnostics and Life Sciences, Danaher Corporation
    BIOGRAPHY
  • JUN 17, 2021 1:00 PM BST

    Panel Q&A: Accelerating diagnostic test development

    Dr. Zahidul Mondle
    Lead Technical Product Specialist, Cytiva
    Dominik de Cassan
    R&D Leader - Membranes, Cytiva
    Lee Jenkins
    Senior Product Leader, Cytiva
    Andrew Gane
    Strategy and Technology Manager, Cytiva
    Chike Ejiofor
    Product Manager Nucleic Acid Sample Preparation, Cytiva
    Matthew Davies
    Custom Service Leader, Cytiva
  • JUN 17, 2021 4:00 PM BST

    Developing an effective regulatory pathway for IVD

    Philippe Etter
    Senior Partner, Medidee
    Dr. Silvia Anghel
    Senior Associate, Medidee
About us

Advancing the development and manufacture of therapeutics

Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.

Improving access to life-changing therapies that transform human health

Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.

Cytiva is a global life sciences leader with over 7000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients.

  • We operate in 40 countries and territories covering Europe, Asia, North and Latin America, and the Middle East.
  • 7,000 associates are dedicated to our mission to advance and accelerate therapeutics.
  • We host 11 customer-centered innovation facilities across Asia, Europe and the Americas to carry ideas through to commercial development

Find out more at Cytiva.com

Collaborators

Abingdon Health is a technology-enabled lateral flow diagnostics company providing leading-edge rapid testing solutions to a multi-industry, global client base. Abingdon Health provides lateral flow assay development and smartphone reader solutions alongside Europe’s largest rapid test manufacturing capacity. A multi-disciplinary team forms the foundations of our services and a partnership-led approach alongside a focus on operational excellence produces reliable products irrespective of their complexity. Established supply chain and manufacturing processes are tailored to assay specifications and market demand for continuity of supply.

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost. Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONTM drug candidate, a targeted form of the standard-of-care Doxorubicin, into the clinic by the first half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics business unit works with partners world-wide to develop Affimer proteins for evaluation by those third parties with the objective of establishing royalty bearing license deals with a particular focus on the diagnostics sector. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

 

BioDot is the leading provider of automated, ultralow-volume, non-contact fluid dispensing platforms for R&D applications and commercial-scale manufacturing across diagnostics and life sciences, medical products and applied industrial markets. Its technologies are integral to production of point-of-care diagnostics for infectious diseases, allergy tests and diabetes maintenance as well as veterinary medicine and environmental applications. BioDot, founded in 1994, is based in Irvine, California and has international offices in Europe and Asia.

 

Biogazelle is a Contract Research Organization (CRO) specializing in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. We hold a unique forefront position in the application of quantitative PCR, digital PCR and dedicated RNA sequencing workflows, optimized for quantification of coding and non-coding genes, on precious clinical samples such as liquid biopsies and formalin-fixed, paraffin-embedded (FFPE) tissues. Our aim is to accelerate the development of therapeutics, including small molecules, RNA targeted drugs, and adoptive cell therapies.

 

Medidee is a leading contract research organization (CRO) and regulatory affairs (RA) and quality assurance (QA) consulting firm for in-vitro diagnostics (IVD) and medical devices with 12 offices in EU, USA and APAC. We deliver strategic, tactical and implementation services to a wide range of global and start-ups. Medidee is very active on MedTech innovation and supports the full product lifecycle from sciences to market. Medidee is at the forefront of the transformation of the IVD industry, including a steep change of regulatory expectations, the digitalization of products and the shift towards the point-of-care.

Help